| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
1 Crucell Holland B.V., Leiden, and 2 Department of Hematology, Free University Medical Center, Amsterdam, the Netherlands
Acute myeloid leukemia (AML) has a poor prognosis due to treatment-resistant relapses. A humanized anti-CD33 antibody (Mylotarg) showed a limited response rate in relapsed AML. To discover novel AML antibody targets, we selected a panel of single chain Fv fragments using phage display technology combined with flow cytometry on AML tumor samples. One selected single chain Fv fragment broadly reacted with AML samples and with myeloid cell lineages within peripheral blood. Expression cloning identified the antigen recognized as C-type lectin-like molecule-1 (CLL-1), a previously undescribed transmembrane glycoprotein. CLL-1 expression was analyzed with a human anti-CLL-1 antibody that was generated from the single chain Fv fragment. CLL-1 is restricted to the hematopoietic lineage, in particular to myeloid cells present in peripheral blood and bone marrow. CLL-1 is absent on uncommitted CD34+/CD38– or CD34+/CD33– stem cells and present on subsets of CD34+/CD38+ or CD34+/CD33+ progenitor cells. CLL-1 is not expressed in any other tissue. In contrast, analysis of primary AMLs demonstrated CLL-1 expression in 92% (68 of 74) of the samples. As an AML marker, CLL-1 was able to complement CD33, because 67% (8 of 12) of the CD33– AMLs expressed CLL-1. CLL-1 showed variable expression (10–60%) in CD34+ cells in chronic myelogenous leukemia and myelodysplastic syndrome but was absent in 12 of 13 cases of acute lymphoblastic leukemia. The AML reactivity combined with the restricted expression on normal cells identifies CLL-1 as a novel potential target for AML treatment.
This article has been cited by other articles:
|
|
 |
|
  A. van Rhenen, G. A. M. S. van Dongen, A. Kelder, E. J. Rombouts, N. Feller, B. Moshaver, M. S.-v. Walsum, S. Zweegman, G. J. Ossenkoppele, and G. Jan Schuurhuis The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells Blood, October 1, 2007; 110(7): 2659 - 2666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Hoffmann, C. Schellack, S. Textor, S. Konold, D. Schmitz, A. Cerwenka, S. Pflanz, and C. Watzl Identification of CLEC12B, an Inhibitory Receptor on Myeloid Cells J. Biol. Chem., August 3, 2007; 282(31): 22370 - 22375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Matmati, W. Pouwels, R. van Bruggen, M. Jansen, R. M. Hoek, A. J. Verhoeven, and J. Hamann The human EGF-TM7 receptor EMR3 is a marker for mature granulocytes J. Leukoc. Biol., February 1, 2007; 81(2): 440 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Chen, H. Floyd, N. E. Olson, D. Magaletti, C. Li, K. Draves, and E. A. Clark Dendritic-cell-associated C-type lectin 2 (DCAL-2) alters dendritic-cell maturation and cytokine production Blood, February 15, 2006; 107(4): 1459 - 1467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. van Rhenen, N. Feller, A. Kelder, G. Westra, L. Bakker, G. Ossenkoppele, and G. J. Schuurhuis The Novel AML Stem Cell Associated Antigen CLL-1 Discriminates between Normal and Leukemic Stem Cells. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 4 - 4. [Abstract]
|
|
|
|
 |
|
 A. van Rhenen, N. Feller, A. Kelder, A. H. Westra, E. Rombouts, S. Zweegman, M. A. van der Pol, Q. Waisfisz, G. J. Ossenkoppele, and G. J. Schuurhuis High Stem Cell Frequency in Acute Myeloid Leukemia at Diagnosis Predicts High Minimal Residual Disease and Poor Survival Clin. Cancer Res., September 15, 2005; 11(18): 6520 - 6527. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
